IRVINE, Calif.--(BUSINESS WIRE)--Sep. 8, 2015--
(NASDAQ: MASI) today announced that its management is scheduled to
present at the Morgan Stanley Global Healthcare Conference at the Grand
Hyatt New York on Friday, September 18, 2015, at 11:05 a.m. Eastern
Time. A live audiocast of the presentation will be available on the
Masimo website at www.masimo.com.
A replay of the audiocast will be available following the live
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies that significantly improve patient care –
helping solve "unsolvable" problems. In 1995, the company debuted
Measure-Through Motion and Low Perfusion™ pulse oximetry, known as
Masimo SET®, which virtually eliminated false alarms and increased pulse
oximetry's ability to detect life-threatening events. More than 100
independent and objective studies have shown that Masimo SET®
outperforms other pulse oximetry technologies, even under the most
challenging clinical conditions, including patient motion and low
peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse
CO-Oximetry technology, allowing noninvasive and continuous monitoring
of blood constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability
Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI).
Additional information about Masimo and its products may be found at www.masimo.com.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome
and Reducing Cost of Care... by Taking Noninvasive Monitoring to New
Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are
trademarks or registered trademarks of Masimo Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150908005196/en/